INNOVATION FOR PATIENTS
About us

Founded in 2018, Angitia is a global clinical-stage biotechnology company focused on the discovery and development of breakthrough and innovative therapeutics that address the unmet medical needs of serious musculoskeletal diseases. Our team consists of dedicated, passionate, and experienced leaders with a proven track record in drug development of musculoskeletal diseases. The company operates in two main locations: Guangzhou, Guangdong, China, and Woodland Hills, California, USA.


Diseases
Degenerative Disc Disease
Osteoporosis
Osteogenesis Imperfecta
Bone Metastasis
Nonunion
Osteoarthritis
Muscle Disorders
Focus on
Musculoskeletal Diseases
More information
Careers
Angita is a global company with a diverse team.
Our company culture revolves around respect and equality.
We are committed to fostering employee growth and career development.
More‧‧‧‧‧
Media
2023.12.08
Angitia Biopharmaceuticals Announces the First Subject Dosed in a Phase III Registrational Trial of AGA111, a Drug Candidate for Enhancing Spinal Fusion
Guangzhou, China and Woodland Hills, California, USA – December 8th, 2023, Angitia Biopharmaceuticals, a global clinical-stage biotechnology company, announced today that the first subject has been successfully dosed in a Phase III registrational clinical trial of AGA111.
2023.10.19
Angitia Biopharmaceuticals Announces Completion of $46M Series B Extension Financing
October 19, 2023 - Angitia Biopharmaceuticals, a global clinical-stage biotechnology company focused on the discovery and development of breakthrough therapies that address the unmet medical needs of patients with serious musculoskeletal disease, announced the closing of a US$46M Series B extension financing led by Morningside Group, and syndicated by 3H Health Investment, OrbiMed, Yonghua Capital, Legend Capital, Oriza Holdings and Elikon Venture. The Series B extension financing brings the total size of the funding round to US$170M. Proceeds from the financing will be used to accelerate the global development of Angitia’s innovative drug candidates for musculoskeletal diseases including AGA111, AGA2115 and AGA2118.
2023.10.17
Angitia Biopharmaceuticals Announces the First Subject Dosed in the Phase Ⅰ trial of AGA2115, a novel biologic for the Treatment of Osteogenesis Imperfecta
Woodland Hills, California, USA – 17 Oct 2023 Angitia Biopharmaceuticals, a global clinical-stage biotechnology company focused on the discovery and development of breakthrough therapies that address the unmet medical needs of patients with serious musculoskeletal disease, announced today that the first subject has been successfully dosed in the Phase Ⅰ clinical trial of AGA2115. The First-in-Human (FIH) trial is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of AGA2115, an investigational therapy for the treatment of osteogenesis imperfecta (OI).
more news...